Medical Condition News

RSS

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

AutoGenomics introduces first automated molecular assay for Familial Mediterranean Fever

AutoGenomics, a leader in providing automated, molecular testing solutions, announced today that it has launched a new test for the identification of genetic mutations implicated in the development of Familial Mediterranean Fever (FMF). The INFINITI® Familial Mediterranean Fever Panel provides simultaneous multiplexed determination of 13 genetic variants common to more than 10 afflicted ethnicities of Mediterranean origin on the automated INFINITI® Analyzer. FMF is prominently present in the Armenian people, Sephardi Jews, Greeks, Arabs and Turks.

21 Dec 2010

Tips to find if a senior relative needs immediate medical attention

You're in from out of town and stop by to see Great Aunt Edna and Great Uncle Albert for the first time in a few years. But you become worried when you observe that the busy, meticulous couple of your youth is gone, replaced by a disheveled woman who won't get out of bed and a belligerent man who doesn't recognize you and thinks it is 1959.

21 Dec 2010

Gym injury prevention advice for the New Year

The American Orthopaedic Foot & Ankle Society (AOFAS) has a message for previously sedentary Americans who will head to the gym this New Year: take it slow. Stress fractures are the most common overuse injuries of the foot and ankle. They occur with a rapid increase in physical activity (too much too quickly). Stress fractures result from a series of loading and unloading cycles that cause damage to the bone. If these forces continue and the bone is not able to repair itself fast enough, a fracture may occur.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

In its recently released annual 2010 update, ChartTrends®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer biologic agents such as UCB's Cimzia and Centocor OrthoBiotech's Simponi, although lagging in overall market share, have begun to penetrate the first line biologic position primarily at the expense of Pfizer/Amgen's Enbrel and Abbott's Humira.

21 Dec 2010

USC researchers analyse radon levels in Galicia secondary schools

Researchers from the University of Santiago de Compostela (USC) have analysed levels of radon, a natural radioactive gas, in 58 secondary schools in Galicia.

21 Dec 2010

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.

21 Dec 2010

Investigator to receive AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award

The American Gastroenterological Association Foundation for Digestive Health and Nutrition announced that Anisa Shaker, MD, is the recipient of the AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award in Gut Physiology and Health.

21 Dec 2010

Simple ways to limit damage due to holiday drinks loaded with calories

But Loyola University Health System registered dietitian Brooke Schantz says there are simple ways to limit the damage. Here is her advice for how to enjoy five popular holiday drinks:

21 Dec 2010

New study finds 80% of transfer cases in Illinois take longer than two hours

Illinois law states that when hospitals need to transfer trauma patients to centers with higher levels of trauma care, such transfers should be made within two hours.

21 Dec 2010

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.

21 Dec 2010

NAMI publishes updated family guide for treating adolescents living with depression

The National Alliance on Mental Illness has published an updated and expanded edition of What Families Need to Know about Adolescent Depression, a guide for families who want to know about accurate diagnosis and effective treatment options for teenagers experiencing depression.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Researchers present definitive explanation of how fibrotic cells destroy human liver

In the latest of a series of related papers, researchers at the University of California, San Diego School of Medicine, with colleagues in Austria and elsewhere, present a new and more definitive explanation of how fibrotic cells form, multiply and eventually destroy the human liver, resulting in cirrhosis. In doing so, the findings upend the standing of a long-presumed marker for multiple fibrotic diseases and reveal the existence of a previously unknown kind of inflammatory white blood cell.

21 Dec 2010

Damon Runyon Cancer Research Foundation names first recipients of Frey Award for Breakthrough Scientists

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named the first recipients of the Dale F. Frey Award for Breakthrough Scientists. This new award provides additional funding to scientists completing a prestigious Damon Runyon Fellowship Award who have greatly exceeded the Foundation's highest expectations and are most likely to make paradigm-shifting breakthroughs that transform the way we prevent, diagnose and treat cancer.

21 Dec 2010

The Lewin Group to perform two-year study on health outcomes in children with ASD

The National Institute of Mental Health has selected The Lewin Group to perform a two-year study on health outcomes in children with autism and their families. The study will describe the range of medical conditions experienced by children with autism spectrum disorders and the health outcomes of the children and their families.

21 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Exiqon A/S today announced the completion of the discovery phase in its program for early detection of colorectal cancer in blood.

21 Dec 2010

Medical Condition News

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

AutoGenomics introduces first automated molecular assay for Familial Mediterranean Fever

Tips to find if a senior relative needs immediate medical attention

Gym injury prevention advice for the New Year

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

USC researchers analyse radon levels in Galicia secondary schools

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

Investigator to receive AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award

Simple ways to limit damage due to holiday drinks loaded with calories

New study finds 80% of transfer cases in Illinois take longer than two hours

Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins

NAMI publishes updated family guide for treating adolescents living with depression

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Researchers present definitive explanation of how fibrotic cells destroy human liver

Damon Runyon Cancer Research Foundation names first recipients of Frey Award for Breakthrough Scientists

The Lewin Group to perform two-year study on health outcomes in children with ASD

Gilenya offers more benefits for MS therapy than previously realized

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News